Top 5 dealmakers in licensing and joint venture for the first half of 2012

Company: Roche/Genentech ($RHHBY)
Total: $1.37B
Partners and announced deal size: Xenon (discovery, $646M), AC Immune (preclinical, $418 million) and Savira (preclinical, $302 million)
Focus: Neurology and infectious diseases, small molecules

Company: Abbott ($ABT)
Total: $1.37B
Partners: Galapagos (Phase II, $1.35B); Apricus ($16M, approved)
Focus: Autoimmune/inflammatory and genitourinary, small molecules


Company: Merck ($MRK)
Total: $1.3 billion
Partners: Endocyte ($1B, Phase III); Ambrx ($303M, Discovery)
Focus: Cancer, small molecules and antibodies

Company: Boehringer Ingelheim
Total: $815M
Partner: Forma Therapeutics
Focus: Cancer discovery, small molecules

Company: Johnson & Johnson ($JNJ)
Partner: Forma Therapeutics
Total: $700M
Focus: Cancer discovery, small molecules

 

Top 5 dealmakers in licensing and joint venture for the first half of 2012
Read more on

Suggested Articles

Karen DeSalvo's appointment is the latest in a string of hires that deepen the tech giant’s investment in and focus on healthcare.

Spring Bank’s hepatitis B drug, given in tandem with Gilead’s Vemlidy, tamped down on chronic disease in 23% of patients in a phase 2 study.

Gilead names Dickinson to CFO role; MedImmune CSO Herbst nabs CSO job at Pyxis; Checkmate picks up Wooldridge for CMO.